Form 4: Philippe Menu Sells SOPHiA GENETICS Shares

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, reported a sale of 5,000 ordinary shares for $4.6689 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Philippe Menu, Chief Medical Officer at SOPHiA GENETICS SA, sold 5,000 ordinary shares.
• The transaction occurred on May 12, 2026, with shares sold at a weighted average price of $4.6689.
• The sale was conducted under a pre-arranged trading plan (Rule 10b5-1(c)) designed to comply with safe harbor provisions.
• Following the transaction, Mr. Menu beneficially owns 256,388 ordinary shares directly.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as slightly negative due to an insider sale, even though it was executed under a Rule 10b5-1 plan, which can temper concerns about opportunistic trading.

Negatives

• A key executive, the Chief Medical Officer, has sold a portion of their holdings.
• The sale represents a reduction in direct beneficial ownership by a company officer.

Risks

• Potential negative signal to the market regarding management's confidence in the company's future performance, despite being executed under a trading plan.
• The sale price of $4.6689 per share may indicate a valuation that some investors find less attractive than previous levels.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transaction was executed under a pre-established trading plan.

Industry Context

StockSavvy.ai notes that insider sales, even those conducted under Rule 10b5-1 plans, are closely watched by the market. While these plans are designed to avoid accusations of insider trading, they can still be interpreted by investors as a signal of management's sentiment towards the company's stock value.

Stakeholder Impact

• Shareholders may view the sale by a key executive as a potential negative signal, potentially impacting short-term stock sentiment.
• Employees may interpret the sale as a sign of reduced confidence from leadership, although the Rule 10b5-1 plan mitigates this concern.

Key Dates

Recommendation

The sale by a key executive, while executed under a Rule 10b5-1 plan, warrants caution. However, without further negative financial disclosures or strategic concerns, a 'hold' recommendation is appropriate, reflecting a neutral stance pending more significant company-specific news.

Keywords

SOPHiA GENETICS, SOPH, Form 4, Insider Trading, Share Sale, Philippe Menu, Chief Medical Officer, Rule 10b5-1, Beneficial Ownership